Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when people with brain cancer will have access to personalised vaccines as part of their NHS treatment.

There are currently no personalised cancer vaccines with a marketing authorisation for use in the United Kingdom. All new, licensed medicines, including personalised cancer vaccines, are evaluated by the National Institute for Health and Care Excellence (NICE) which makes recommendations on whether they should be routinely funded by the National Health Service, based on an assessment of clinical and cost effectiveness. NICE aims wherever possible to issue recommendations on new medicines close to the point of licensing, and cancer medicines are eligible for funding from the Cancer Drugs Fund from the point of a positive draft NICE recommendation, bringing forward patient access by up to five months.

The measures that we announced in the Life Sciences Sector Plan will enhance NICE’s collaboration with the Medicines and Healthcare products Regulatory Agency and will support faster access to medicines for NHS patients in England.

Further, the NHS Cancer Vaccine Launch Pad (CVLP) is a platform set up to accelerate the development of cancer vaccines and speed up access to mRNA personalised cancer vaccine clinical trials for cancer patients. The CVLP has been instrumental in accelerating trial activity in cancer research, with CVLP sites driving faster activation and enrolment timelines. The platform is designed to be company- and clinical trial type-agnostic. Any company that wishes to deliver trials via the platform, including those developing vaccines for brain tumours, can contact the CVLP to explore how the platform can support their research.